SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 8-K


                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934
                        Date of Report: November 4, 1999



                                 MEDIMMUNE, INC.
             (Exact name of registrant as specified in its charter)



                         Commission File Number: 0-19131




                   Delaware                          52-1555759
             (State of Incorporation)              (I.R.S. Employer
                                                   Identification No.)



                35 West Watkins Mill Road, Gaithersburg, MD 20878
                (Address of principal executive office (Zip Code)


Registrant's telephone number, including area code (301) 417-0770


No Exhibits are being filed with this report


CytoGam, RespiGam and Synagis are registered trademarks of the Company.

<PAGE>

MEDIMMUNE, INC.
Current Report on Form 8-K

ITEM 5.  OTHER EVENTS

MedImmune,  Inc.  reported  the  information  contained in the  following  press
release dated November 4, 1999:

FOR IMMEDIATE RELEASE



          SAFETY AND EFFICACY OF SYNAGIS (palivizumab) REAFFIRMED AFTER
                 FIRST SEASON'S USE; MEDIMMUNE PRESENTS DATA AT
             SECOND WORLD CONGRESS OF PEDIATRIC INFECTIOUS DISEASES

Data Presented
o    Efficacy and Safety Data from First Season of Use in United States
o    Results of an Expanded Access Study in 15 Countries

Gaithersburg,  MD, November 4, 1999 - MedImmune,  Inc. (Nasdaq:  MEDI) announced
that additional safety and efficacy data on the use of Synagis (palivizumab) for
the prevention of serious respiratory syncytial virus (RSV) disease in pediatric
patients at high risk for RSV disease was presented at the Second World Congress
of  Pediatric  Infectious  Diseases  in  Manila,  November  2-6,  1999 (see full
prescribing information at  www.medimmune.com/medimmune/products/synagispi.htm).
Data  presented  included the clinical  outcomes of patients  receiving  Synagis
during the 1998/1999  RSV season,  the drug's first season of general use in the
United  States.  Also  presented  were data from an Expanded  Access Study in 15
countries where Synagis was not yet available during the 1998/1999  season.  All
data presented at the World Congress affirm the results  observed in MedImmune's
pivotal Phase 3 trial (Impact-RSV),  which demonstrated that Synagis is safe and
effective in reducing RSV hospitalizations in all defined population subgroups.

"We are obviously pleased with the results of these studies," commented Franklin
H. Top, Jr., M.D.,  MedImmune's  executive vice president and medical  director,
"since they indicate that Synagis is effective in actual clinical practice, just
as it was efficacious in clinical trials.  Also, safety data from our compliance
program confirm in much larger numbers of children the excellent  safety profile
seen in clinical trials.  Both  pediatricians and parents of children at risk of
RSV disease can have  increased  confidence of the safety and  effectiveness  of
Synagis as we enter its second season of clinical use."


First Year Experience  with Synagis in the United States
---------------------------------------------------------
The abstract entitled "First Year Experience Using Synagis Palivizumab Humanized
Monoclonal  Antibody for Protection From RSV Lower Respiratory Tract Infection,"
Alan Cohen, M.D., et al., and the Synagis Outcomes Survey Group,  reports on two
surveys  performed to evaluate the clinical  effectiveness of Synagis during the
1998/1999 RSV season. The first survey involved a thorough chart review of 1,839
patients from nine U.S. sites,  representing  all patients given Synagis at each
site.  All evaluated  patients were <=35 weeks  gestational  age and received at
least one dose of Synagis  between  September 1998 and May 1999. The data showed
that the RSV  hospitalization  rate in all  patients  receiving  Synagis was 2.3
percent. This compares favorably to RSV hospitalization rates of 4.8 percent and
10.6  percent  for  patients  receiving  Synagis  and those  receiving  placebo,
respectively,  in the  IMpact-RSV  trial.  Only  0.5  percent  of  the  patients
receiving Synagis spent any time in intensive care due to RSV disease.

The  second  set of data  surveyed  came  from  safety  reports  in  MedImmune's
compliance  program  called the REACH Program  (Registered)  (RSV  Education and
Compliance Helpline),  which included 7,013 patients who received Synagis during
the 1998-1999 RSV season and whose parents were  contacted on a regular basis to
monitor  compliance with their physician's  prescribing  orders.  Adverse events
reported  in  these  children  were  similar  to  those  identified  in both the
treatment and placebo groups of the Impact-RSV  trials.  Only 1.5 percent of the
children  enrolled in the REACH Program were reported to have been  hospitalized
due to RSV infection.

Expanded Access Study in 1998/1999 in the Northern Hemisphere
-------------------------------------------------------------
The abstract entitled  "Palivizumab  (Synagis)-Expanded  Access Study in 1998-99
Northern Hemisphere," Barbara J. Law, M.D., et al., provides data from a Phase 4
study  initiated  during the 1998/1999 RSV season to collect  additional  safety
data in 15 countries where Synagis was not yet readily available. A total of 565
children were  enrolled at 77 centers in this  single-arm,  open-labeled  study.
Forty-one patients were hospitalized with respiratory  illness during the study:
seven were RSV-positive,  20 were RSV-negative,  and 14 were not tested for RSV.
If the 14 patients not tested for RSV were assumed to all be RSV  positive,  the
maximum RSV  hospitalization  rate would be 3.7 percent in this study, while the
actual confirmed RSV hospitalization  rate was 1.2 percent.  These results again
compare  favorably  to the 4.8 percent  RSV  hospitalization  rate for  patients
treated with Synagis in MedImmune's pivotal clinical trial.

The Expanded Access Study broadens the geographical  region in which Synagis has
been  evaluated.   Twenty-five  countries  have  approved  Synagis  for  use  in
preventing RSV infection in high-risk  children.  Applications for approval have
been submitted in 19 additional countries.

Synagis is a humanized  monoclonal  antibody  used in the  prevention of serious
lower respiratory tract disease caused by RSV in pediatric patients at high risk
of RSV disease,  the most common cause of pneumonia and bronchiolitis in infants
and children.  Synagis is the first  monoclonal  antibody to be licensed for any
infectious disease. It is administered by intramuscular injection once per month
during anticipated periods of RSV prevalence,  which typically runs from October
through April in the United States, where there are over 300,000 infants at risk
of contracting  the disease.  In the United States,  MedImmune  co-promotes  the
product  with the Ross  Products  Division  of Abbott  Laboratories  (NYSE:ABT).
Outside the U.S., Abbott  International  owns an exclusive license to market the
product.

MedImmune,  Inc. is a biotechnology  company located in  Gaithersburg,  Maryland
focused on developing and marketing products that address medical needs in areas
such as infectious disease,  transplantation medicine,  autoimmune disorders and
cancer.  The company  currently  markets  three  products  and has five  product
candidates in clinical trials.  This  announcement  may contain,  in addition to
historical information,  certain  forward-looking  statements that involve risks
and uncertainties.  Such statements reflect  management's  current views and are
based on certain assumptions.  Actual results could differ materially from those
currently  anticipated as a result of a number of factors,  including  risks and
uncertainties  discussed in the company's  filings with the U.S.  Securities and
Exchange Commission. MedImmune cautions that RSV disease occurs primarily during
the winter months;  the company believes its operating  results will continue to
reflect that seasonality for the foreseeable future.



                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                         MEDIMMUNE, INC.
                         ----------------
                         (Registrant)



November 8, 1999        ________________________________
                        David M. Mott, Vice Chairman and
                        Chief Financial Officer
[{"type": "8-K", "sequence": "1", "description": "SAFETY AND EFFICACY OF SYNAGIS", "secsgml_size_bytes": 8888}]
{"company-data": {"conformed-name": "MEDIMMUNE INC /DE", "cik": "0000873591", "assigned-sic": "2836", "irs-number": "521555759", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-14657", "film-number": "99742816"}, "business-address": {"street1": "35 W WATKINS MILL RD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878", "phone": "3014170770"}, "mail-address": {"street1": "35 W WATKINS MILL ROAD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878"}}
SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934
                        Date of Report: November 4, 1999

                                 MEDIMMUNE, INC.
             (Exact name of registrant as specified in its charter)

                         Commission File Number: 0-19131

                   Delaware                          52-1555759
             (State of Incorporation)              (I.R.S. Employer
                                                   Identification No.)

                35 West Watkins Mill Road, Gaithersburg, MD 20878
                (Address of principal executive office (Zip Code)

Registrant's telephone number, including area code (301) 417-0770

No Exhibits are being filed with this report

CytoGam, RespiGam and Synagis are registered trademarks of the Company.
MEDIMMUNE, INC.
Current Report on Form 8-K

ITEM 5.  OTHER EVENTS

MedImmune,  Inc.  reported  the  information  contained in the  following  press
release dated November 4, 1999:

FOR IMMEDIATE RELEASE

          SAFETY AND EFFICACY OF SYNAGIS (palivizumab) REAFFIRMED AFTER
                 FIRST SEASON'S USE; MEDIMMUNE PRESENTS DATA AT
             SECOND WORLD CONGRESS OF PEDIATRIC INFECTIOUS DISEASES

Data Presented
o    Efficacy and Safety Data from First Season of Use in United States
o    Results of an Expanded Access Study in 15 Countries

Gaithersburg,  MD, November 4, 1999 - MedImmune,  Inc. (Nasdaq:  MEDI) announced
that additional safety and efficacy data on the use of Synagis (palivizumab) for
the prevention of serious respiratory syncytial virus (RSV) disease in pediatric
patients at high risk for RSV disease was presented at the Second World Congress
of  Pediatric  Infectious  Diseases  in  Manila,  November  2-6,  1999 (see full
prescribing information at  www.medimmune.com/medimmune/products/synagispi.htm).
Data  presented  included the clinical  outcomes of patients  receiving  Synagis
during the 1998/1999  RSV season,  the drug's first season of general use in the
United  States.  Also  presented  were data from an Expanded  Access Study in 15
countries where Synagis was not yet available during the 1998/1999  season.  All
data presented at the World Congress affirm the results  observed in MedImmune's
pivotal Phase 3 trial (Impact-RSV),  which demonstrated that Synagis is safe and
effective in reducing RSV hospitalizations in all defined population subgroups.

"We are obviously pleased with the results of these studies," commented Franklin
H. Top, Jr., M.D.,  MedImmune's  executive vice president and medical  director,
"since they indicate that Synagis is effective in actual clinical practice, just
as it was efficacious in clinical trials.  Also, safety data from our compliance
program confirm in much larger numbers of children the excellent  safety profile
seen in clinical trials.  Both  pediatricians and parents of children at risk of
RSV disease can have  increased  confidence of the safety and  effectiveness  of
Synagis as we enter its second season of clinical use."

First Year Experience  with Synagis in the United States
---------------------------------------------------------
The abstract entitled "First Year Experience Using Synagis Palivizumab Humanized
Monoclonal  Antibody for Protection From RSV Lower Respiratory Tract Infection,"
Alan Cohen, M.D., et al., and the Synagis Outcomes Survey Group,  reports on two
surveys  performed to evaluate the clinical  effectiveness of Synagis during the
1998/1999 RSV season. The first survey involved a thorough chart review of 1,839
patients from nine U.S. sites,  representing  all patients given Synagis at each
site.  All evaluated  patients were <=35 weeks  gestational  age and received at
least one dose of Synagis  between  September 1998 and May 1999. The data showed
that the RSV  hospitalization  rate in all  patients  receiving  Synagis was 2.3
percent. This compares favorably to RSV hospitalization rates of 4.8 percent and
10.6  percent  for  patients  receiving  Synagis  and those  receiving  placebo,
respectively,  in the  IMpact-RSV  trial.  Only  0.5  percent  of  the  patients
receiving Synagis spent any time in intensive care due to RSV disease.

The  second  set of data  surveyed  came  from  safety  reports  in  MedImmune's
compliance  program  called the REACH Program  (Registered)  (RSV  Education and
Compliance Helpline),  which included 7,013 patients who received Synagis during
the 1998-1999 RSV season and whose parents were  contacted on a regular basis to
monitor  compliance with their physician's  prescribing  orders.  Adverse events
reported  in  these  children  were  similar  to  those  identified  in both the
treatment and placebo groups of the Impact-RSV  trials.  Only 1.5 percent of the
children  enrolled in the REACH Program were reported to have been  hospitalized
due to RSV infection.

Expanded Access Study in 1998/1999 in the Northern Hemisphere
-------------------------------------------------------------
The abstract entitled  "Palivizumab  (Synagis)-Expanded  Access Study in 1998-99
Northern Hemisphere," Barbara J. Law, M.D., et al., provides data from a Phase 4
study  initiated  during the 1998/1999 RSV season to collect  additional  safety
data in 15 countries where Synagis was not yet readily available. A total of 565
children were  enrolled at 77 centers in this  single-arm,  open-labeled  study.
Forty-one patients were hospitalized with respiratory  illness during the study:
seven were RSV-positive,  20 were RSV-negative,  and 14 were not tested for RSV.
If the 14 patients not tested for RSV were assumed to all be RSV  positive,  the
maximum RSV  hospitalization  rate would be 3.7 percent in this study, while the
actual confirmed RSV hospitalization  rate was 1.2 percent.  These results again
compare  favorably  to the 4.8 percent  RSV  hospitalization  rate for  patients
treated with Synagis in MedImmune's pivotal clinical trial.

The Expanded Access Study broadens the geographical  region in which Synagis has
been  evaluated.   Twenty-five  countries  have  approved  Synagis  for  use  in
preventing RSV infection in high-risk  children.  Applications for approval have
been submitted in 19 additional countries.

Synagis is a humanized  monoclonal  antibody  used in the  prevention of serious
lower respiratory tract disease caused by RSV in pediatric patients at high risk
of RSV disease,  the most common cause of pneumonia and bronchiolitis in infants
and children.  Synagis is the first  monoclonal  antibody to be licensed for any
infectious disease. It is administered by intramuscular injection once per month
during anticipated periods of RSV prevalence,  which typically runs from October
through April in the United States, where there are over 300,000 infants at risk
of contracting  the disease.  In the United States,  MedImmune  co-promotes  the
product  with the Ross  Products  Division  of Abbott  Laboratories  (NYSE:ABT).
Outside the U.S., Abbott  International  owns an exclusive license to market the
product.

MedImmune,  Inc. is a biotechnology  company located in  Gaithersburg,  Maryland
focused on developing and marketing products that address medical needs in areas
such as infectious disease,  transplantation medicine,  autoimmune disorders and
cancer.  The company  currently  markets  three  products  and has five  product
candidates in clinical trials.  This  announcement  may contain,  in addition to
historical information,  certain  forward-looking  statements that involve risks
and uncertainties.  Such statements reflect  management's  current views and are
based on certain assumptions.  Actual results could differ materially from those
currently  anticipated as a result of a number of factors,  including  risks and
uncertainties  discussed in the company's  filings with the U.S.  Securities and
Exchange Commission. MedImmune cautions that RSV disease occurs primarily during
the winter months;  the company believes its operating  results will continue to
reflect that seasonality for the foreseeable future.

                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                         MEDIMMUNE, INC.
                         ----------------
                         (Registrant)

November 8, 1999        ________________________________
                        David M. Mott, Vice Chairman and
                        Chief Financial Officer